Seroprevalences of hepatitis B virus and hepatitis C virus among participants of an Asian health fair in the Lower Mainland, British Columbia

Stephen Ip MD1, Jo-Ann Ford MSN1, Kirby Lau BSc1, Vladimir Marquez MDCM MSc1, Marisa Guan MD1, Carolyn Klassen MSN1, Jessica Chan MD2, WC Peter Kwan MD3, Mel Krajden MD3, Eric M Yoshida MD1

BACKGROUND: The seroprevalences of hepatitis B virus (HBV) and hepatitis C virus (HCV) are 0.4% and 0.8%, respectively, in Canada, but varying rates have been reported in different populations.

OBJECTIVES: To determine the seroprevalences of HBV and HCV among attendees of an Asian health fair in the Lower Mainland, British Columbia, as well as to correlate vaccination status to serological profiles.

METHODS: Attendees at an Asian health fair were invited to participate in the present study on a voluntary basis. They provided answers to a questionnaire including ethnicity and vaccination status. Blood was then drawn for HBV and HCV serology. Active HBV was defined as HBV surface antigen (HBsAg) positive while HBV serorevalence was defined as HCV antibody reactive. Previous exposure to HBV was defined as HBV core antibody (anti-HBc) positive and HBsAg negative. Nonimmunity was defined as anti-HBc negative and HBV surface antibody negative. Only those with correct demographic information matched to serological results were included in the study.

RESULTS: There were 192 consenting attendees of the fair, of whom 112 were included in the study. Of the participants, 91% were Chinese. Active HBV infection was found in three participants (2.7% [95% CI 0.6% to 7.6%]) and HCV infection was found in two participants (1.8% [95% CI 0.2% to 6.3%]). More than 40% of participants had been previously exposed to HBV (42% [95% CI 33% to 51%]). Almost 20% demonstrated nonimmunity to HBV (19% [95% CI 12% to 27%]). There was significant discordance when questionnaire answers regarding vaccination status were compared with serological profiles.

CONCLUSION: The seroprevalences of HBV and HCV in this cohort were 2.7% and 1.8%, respectively – higher than nationally reported rates. Our results highlight that the lack of knowledge of HBV infection and vaccination status remains a significant clinical issue in the Asian community of British Columbia.

Key Words: Hepatitis B, Hepatitis C, Seroprevalence

According to the Public Health Agency of Canada (1,2), the seroprevalences of hepatitis B virus (HBV) and hepatitis C virus (HCV) in Canada are estimated to be 0.4% and 0.8%, respectively; however, rates may vary significantly, with rates of chronic HBV as high as 5% to 15% being reported among Southeast Asian Canadians (Chinese and Vietnamese). Because at-risk populations for hepatitis (eg, certain ethnic groups) may be less likely to participate in epidemiological studies, HBV and HCV seroprevalences may be under-reported (1-3). Data regarding these populations are lacking in Canada. In a recent study at our centre (Vancouver General Hospital, 1Department of Medicine, Division of Gastroenterology, University of British Columbia; 2United Chinese Community Enrichment Services Society (SUCCESS); 3BC Centre for Disease Control, Vancouver, British Columbia

Correspondence: Dr Eric M Yoshida, Division of Gastroenterology, Vancouver General Hospital, University of British Columbia, 5th Floor, 2775 Laurel Street, Vancouver, British Columbia V5Z 1M9. Telephone 604-875-5371, fax 604-875-5447, e-mail eric.yoshida@vch.ca

OPEN ACCESS This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (http://creativecommons.org/licenses/by-nc/4.0/), which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes. For commercial reuse, contact support@pulsus.com

Can J Infect Dis Med Microbiol Vol 26 No 4 July/August 2015
Vancouver, British Columbia (BC), the seroprevalences of HBV and HCV in admitted patients were higher than those in the general population (4). Therefore, we aimed to assess the seroprevalences of HBV and HCV in the community setting, among attendees at an Asian health fair. Given that this health fair was directed to the Asian community and provided both general medical and hepatitis information with discussions translated in both Cantonese and Mandarin, it would likely capture a population that may be underrepresented in previous studies.

METHODS

The United Chinese Community Enrichment Services Society (SUCCESS), a nonprofit charitable organization in BC, holds an annual health fair in the Lower Mainland of BC. The present study was undertaken during one of these health fairs, held at a local community centre in September 2014. This health fair featured talks and discussions by physicians, including gastroenterologists, and other health care professionals, as well as display booths from various sponsors/supporters and private organizations. These lectures were translated in English, Cantonese and Mandarin. Advertisement for this event, including the availability of viral hepatitis testing, was circulated by radio, newspaper, the SUCCESS website and television announcements, as well as posters with full details posted throughout the community.

Attendees at this health fair who were interested in viral hepatitis testing were presented to the viral hepatitis testing booth. These participants provided voluntary consent if they were interested in participating in the study. Volunteers were present to provide proper translation in English, Cantonese and Mandarin, if necessary. Study participants provided demographic information including age, ethnicity and years of residency in Canada. They also completed a questionnaire that documented whether they had previously participated in hepatitis testing, as well as had undergone vaccination(s) against hepatitis. If a family physician and/or specialist cared for the participant, this information was also recorded. If participants allowed serological information (HBV and HCV serology) to be collected and compared with their questionnaire results.

If attendees were not interested in the study, they were allowed to have serology drawn nonetheless, but these serological results were not collected for the study and these individuals did not complete the questionnaire. Two individuals who presented to the booth for viral hepatitis testing did not wish to participate in the study. Their family doctor or a prearranged walk-in clinic followed up with their serological results.

Attendees were not asked to participate in the study when they entered the doors of the community hall, but they had the opportunity to present to the viral hepatitis testing booth (as well as other booths) and participate if interested. In general, the majority of attendees presented for viral testing; therefore, participants in the present study would be expected to be similar to other attendees.

Blood was drawn for HBV and HCV serology for evaluation by the BC Centre for Disease Control (BCCDC). Results were sent to participants’ respective family physicians to ensure proper follow-up care. Those without a family physician had their results forwarded to a prearranged walk-in clinic. Only those with correct demographic information matched to results from the BCCDC were included in the study. The BCCDC required at least two personal identifying data to be correct (name, date of birth or provincial health number) for serological results to be released. The responses of participants from the questionnaires were then compared with their respective serological profiles.

Active HBV infection was defined as HBV surface antigen positive (HBsAg+). Previous HBV exposure was defined as HBV core antibody positive (anti-HBc+) and HBsAg negative (HBsAg−). Natural immunity was defined as previous HBV exposure with HBV surface antibody positivity (anti-HBc+ and anti-HBs+, ≥10 IU/mL) while HBV immunity by vaccination was defined as anti-HBs+, HBsAg− and anti-HBc−. Nonimmunity to HBV was defined as HBV surface antibody negative (anti-HBs− <3 IU/mL), HBsAg− and anti-HBc−. HCV seroprevalence was defined as being HCV antibody reactive.

Comparisons among response groups were calculated using Fisher’s exact test with GraphPad Prism (GraphPad Inc, USA); P<0.05 was considered to be statistically significant.

The present study was approved by the Clinical Research Ethics Board of the University of British Columbia (Vancouver, BC).

RESULTS

There were 192 participants who consented, of whom 112 (58%) were included in the study. The other participants were excluded because demographic information from the BCCDC did not completely match information collected from the health fair; thus, these data were considered to be inaccurate.

Among the 112 participants, the median age was 65 years (interquartile range 58 to 70 years). There was an approximately equal distribution with regard to sex. The majority (91%) of participants were Chinese, of whom 74% spoke Cantonese and 26% spoke Mandarin; the remaining 9% were Korean. These participants had resided in Canada for an average of 22 years. Almost all of the participants (97%) had a family physician.

| TABLE 1 | Results of the hepatitis questionnaire (n=112) |
|---------|-----------------------------------------------|
| Questions | Yes | No |
| Tested for hepatitis previously? | 26 (23) | 46 (41) | 40 (36) |
| Told you were carrier or had chronic hepatitis? | 7 (6) | 74 (66) | 31 (28) |
| Has physician for hepatitis? | 3/7 (43%) | 47/57 (0) | 0 (0) |
| Been vaccinated for hepatitis previously? | 32 (29) | 21 (19) | 59 (53) |

Among those who stated they had been vaccinated previously, what vaccines did they receive? (n=32)

| Partial hepatitis A virus, partial hepatitis B virus† | 5 (16) |
| Partial hepatitis A virus, complete hepatitis B virus | 1 (3) |
| Partial hepatitis A virus | 2 (6) |
| Partial hepatitis B virus | 4 (13) |
| Complete hepatitis A virus | 3 (10) |
| Complete hepatitis B virus | 12 (38) |
| Complete hepatitis A virus and hepatitis B virus | 5 (16) |

Data presented as n/n (%) or n (%). †Percentage calculated from seven participants. *Percentage calculated from 32 participants

| TABLE 2 | Seroprevalence among participants (n=112) |
|---------|------------------------------------------|
| Serology | n (%) | 95% CI |
| Active HBV (HBsAg+) | 3 (2.7) | (0.6–7.6) |
| HBV exposure (HBsAg−, anti-HBc+, anti-HBs+/anti-HBs−) | 47 (42) | (33–51) |
| HBV natural immunity (anti-HBs+) | 41/47 (87) | (75–95) |
| HBV exposure but no immunity (anti-HBs−) | 6/47 (13) | (5.3–25) |
| HBV immunity by vaccination (HBsAg−, anti-HBc− and anti-HBs+) | 41 (37) | (28–46) |
| HBV nonimmunity (HBsAg−, anti-HBs− and anti-HBc−) | 21 (19) | (12–27) |
| HCV seroprevalence (anti-HCV+) | 2 (1.8) | (0.2–6.3) |

*Percentage calculated with respect to 47 participants. Anti-HBc (+)/ Anti-hepatitis B core total antibodies (positive or negative); Anti-HBs (+)/ Anti-hepatitis B surface antibody (positive or negative); Anti-HCV+ Anti-hepatitis C antibody positive; HBsAg (+)/ Hepatitis B surface antigen (positive or negative); HBV Hepatitis B virus; HCV Hepatitis C virus
Table 3: Correlation of questionnaire results and hepatitis B virus (HBV) serology

| Have you ever been tested for hepatitis? (n=112) | Yes | No | Unknown | P     |
|-------------------------------------------------|-----|----|---------|-------|
| Nonimmunity*                                     | 22/6 (7.7) | 17/46 (37) | 3/40 (7.5) | <0.01 |
| Exposed to HBV                                   | 15/26 (58) | 18/46 (39) | 18/40 (45) | 0.42  |
| Immune by vaccination                            | 9/26 (35) | 11/46 (24) | 19/40 (48) | 0.07  |

| Have you ever been told you are a hepatitis carrier or have chronic hepatitis? (n=112) | Yes | No | Unknown | P     |
|------------------------------------------------------------------------------------------|-----|----|---------|-------|
| Nonimmunity                                                                             | 0/7 (0) | 19/74 (26) | 2/31 (6.5) | <0.01 |
| Exposed to HBV                                                                          | 7/7 (100) | 28/74 (38) | 15/31 (48) | <0.01 |
| Immune by vaccination                                                                   | 0/7 (0) | 27/74 (36) | 14/31 (45) | <0.01 |

Have you had partial or complete vaccination to HBV?

|                     | Complete vaccination (n=18) | Partial vaccination (n=9) | No (n=26) | Unknown (n=59) | P     |
|---------------------|-----------------------------|--------------------------|-----------|----------------|-------|
| Nonimmunity         | 4 (22)                      | 0 (0)                    | 7 (27)    | 10 (17)        | 0.34  |
| Exposed to HBV      | 3 (17)                      | 4 (44)                   | 17 (65)   | 26 (44)        | 0.01  |
| Immune by vaccination| 11 (61)                     | 5 (55)                   | 2 (7.7)   | 24 (41)        | <0.01 |

Data presented as n/n (%) or n (%) unless otherwise indicated. *Nonimmunity was defined as anti-hepatitis B core total antibodies negative and anti-hepatitis B surface antibody negative. †Exposed to HBV was defined as anti-hepatitis B core total antibodies positive, anti-hepatitis B surface antibody negative and; and hepatitis B surface antigen (positive or negative); ‡Immune by vaccination was defined as anti-hepatitis B core total antibodies negative and anti-hepatitis B surface antibody positive; HBV Hepatitis B virus

Questionnaire results showed that 23% of the participants had been previously tested for hepatitis while 36% were unsure whether they had been tested (Table 1). A small percentage of participants (6%) had been told they were carriers or had chronic hepatitis, but only 43% of these individuals were being followed by their family physician or specialist with respect to their diagnosis. Nearly 30% of participants stated that they had been previously vaccinated for hepatitis A virus and/or HBV. Most commonly, they stated that they had complete vaccinations against HBV (38%).

Active HBV was found in three participants (2.7% [95% CI 0.6% to 7.6%]) and HCV infection was found in two participants (1.8% [95% CI 0.2% to 6.3%]) (Table 2). These cases of chronic hepatitis were previously known before testing, except for one new case of HCV. Only 60% of these individuals were followed by their family physician and/or specialist regarding their hepatitis. Surprisingly, 42% (95% CI 33% to 51%) of participants had been previously exposed to HBV, of whom six (13%) had no natural immunity (ie, anti-HBs−). More than one-third of participants (37% [95% CI 28% to 46%]) in the cohort had been vaccinated for HBV while 19% (95% CI 12% to 27%) had a serological panel consistent with no previous HBV vaccination or exposure to the virus (Table 2). Among participants who were anti-HBs+, the average level of these antibodies was 198 mIU/mL (95% CI 104 mIU/mL to 292 mIU/mL).

The correlation of questionnaire answers with serology results is presented in Table 3. The rate of HBV to HBV was higher among participants who stated that they had never been tested for hepatitis compared with those who said they had been tested or that they did not know (37% versus 7.7% versus 7.5%, respectively; P<0.01). Otherwise, there were no other significant differences in the groups with respect to this question.

When participants were asked whether they had ever told that they were a hepatitis carrier or had chronic hepatitis, all seven individuals who answered "yes" had evidence of being previously exposed to HBV (four participants) or had active HBV (three participants) (Table 3). The study participant with known HCV was accounted for in the former group and was not followed by his family doctor and/or specialist with respect to his positive anti-HCV result. The three participants with active HBV were followed by their family doctor and/or specialist with respect to their chronic hepatitis. Among the group who answered "no" or "unknown" to the same question, there were 28 (38%) and 15 (48%) individuals, respectively, who were exposed to HBV. Similarly, there were 19 (26%) and two (6.4%) individuals, respectively, who had no immunity to HBV.

When participants were asked a question about chronic hepatitis and of older age would not have been expected to have been vaccinated. Since), the participants in our study who were born outside of the country infant vaccination approximately 15 years ago (depending on the prov-
Another possible explanation is unawareness of this disease among the population, which has been associated with HCV infection (3,15). In our study, we found that 42% of participants have been previously exposed to HBV. This proportion is substantially higher than the rate of 4.2% reported previously among all Canadians (3). The individuals in our cohort may have seroconverted their HBsAg spontaneously, given the large proportion of participants who were exposed to the virus (ie, anti-HBc+) but were HBsAg-. This may have occurred via acute HBV infection (eg, sexual relations with an HBV carrier or vertical transmission from mother to child) with immune clearance in which the patient was asymptomatic and/or did not seek medical attention. In a small minority of chronic HBV carriers, HBsAg seroconversion may also have occurred spontaneously after many decades. Although immunity may wane over five to 10 years, these individuals had no serological evidence of any protective antibodies. Occult HBV infection may also explain an isolated elevated anti-HBs level; however, HBV DNA or liver enzyme levels were not measured to help differentiate this entity.

In addition, our study demonstrated that approximately 40% of these individuals were unaware of their HBV exposure – these participants answered that they had not been tested for hepatitis or did not know their status. This previous exposure to HBV may lead to reactivation of HBV in the context of immunosuppression, causing severe or potentially fatal liver disease (8-10). Patients who will undergo chemotherapy, immunosuppression, or receive stem cell or solid organ transplantation should be screened for HBV (HBsAg and anti-HBc) (10).

Our study also found significant discordance between questionnaire answers regarding vaccination status and actual serological results (Table 3). For example, 22% of participants who stated they had complete vaccinations to HBV had no serological evidence of protective antibodies. In addition, there may be misunderstanding on the part of the study participants and/or misinformation by the family physician regarding vaccination status. Three study participants were told they had been a hepatitis carrier or had chronic hepatitis; however, they had only been exposed to HBV, with no evidence of active HBV. Our findings corroborate previous studies that have demonstrated that knowledge of HBV is limited in the Asian population (11), even among those with chronic HBV (12,13). The risk of social stigma has also been attributed to reduced HBV screening in the Asian community (14). Thus, continuing education of physicians and patients regarding viral hepatitis as well as encouragement of screening remain important issues in the Asian community in BC.

With regard to HCV, our seroprevalence rate was higher than previous reports (3,15). In a Canadian study examining 15 cities, the seroprevalence of HCV was reported to be 0.3% (3). Uhanova et al (15) reported the same rate from an administrative database of Manitoba from 1995 to 2002. The relatively higher HCV rate in our cohort may have been previously exposed to HBV or HCV infection, such as socioeconomic status, among the Asian and/or immigrant populations. Local hepatitis screening programs aimed at this population will also be an important consideration for health care spending and resource allocation. Finally, ongoing education of HBV and HCV, such as the translated lectures and discussions at this Asian health fair, will be a critical aspect of ongoing medical care among this population. Further education of primary care physicians and counselling of patients will help promote knowledge of viral hepatitis and accurate dissemination of health information.

CONCLUSION

The seroprevalences of HBV and HCV found at an Asian health fair in the Lower Mainland of BC were 2.7% and 1.8%, respectively. Our results highlight that the lack of knowledge of HBV infection and vaccination status remains a significant clinical issue in the Asian community of BC.

ACKNOWLEDGEMENTS: The authors thank all participants in this study as well as the countless volunteers at this Asian health fair.

REFERENCES

1. Brief Report: Hepatitis B in Canada. Public Health Agency of Canada. 2011. <www.phac-aspc.gc.ca/id-mi/hepatitisBCan-hepatiteBCan-eng.php> (Accessed November 2014).
2. Hepatitis C in Canada: 2005-2010 Surveillance Report. Public Health Agency of Canada. 2012. <www.phac-aspc.gc.ca/iti-situs-surv-epi/hepc-surv-eng.php> (Accessed November 2014).
3. Rotermann M, Langlois K, Andonov A, et al. Seroprevalence of hepatitis B and C virus infections: Results from the 2007 to 2009 and 2009 to 2011 Canadian Health Measures Survey. Health Rep 2013;24:3-13.
4. Kapluto J, Kadatz M, Wormsbecker A. Screening, detecting and enhancing the yield of previously undiagnosed hepatitis B and C in patients with acute medical admissions to hospital: A pilot project undertaken at the Vancouver General Hospital. Can J Gastroenterol Hepatol 2014;28:315-8.
5. Glasgow KW, Schabas R, Williams DC, et al. Population-based hepatitis B seroprevalence and risk factor study in a northern Ontario town. Can J Public Health 1997;88:87-90.
6. Chiavetta JA, Escobar M, Newman A, et al. Measles surveillance in a multicultural community in the Lower Mainland of BC. Can J Infect Dis Med Microbiol 2015;26:723-6.
9. Yoshida EM, Ramji A, Erb SR, et al. De novo acute hepatitis B infection in a previously vaccinated liver transplant recipient due to a strain of HBV with a Met 133 Thr mutation in the "a" determinant. Liver 2000;20:411-4.

10. Di Bisceglie AM, Lok AS, Martin P, et al. Recent FDA warnings on hepatitis B reactivation with immune-suppressing and anti-cancer drugs: Just the tip of the iceberg? Hepatology 2015;61:703-11.

11. Cheung J, Lee TK, Teh CZ, et al. Cross-sectional study of hepatitis B awareness among Chinese and Southeast Asian Canadians in the Vancouver-Richmond community. Can J Gastroenterol 2005;19:245-9.

12. Kue J, Thorburn S. Hepatitis B knowledge, screening, and vaccination among Hmong Americans. J Health Care Poor Underserved 2013;24:566-78.

13. Tokes K, Quadri S, Cahill P, et al. Disease and treatment perceptions among Asian Americans diagnosed with chronic hepatitis B. J Gen Intern Med 2014;29:87-84.

14. Li D, Tang T, Patterson M, et al. The impact of hepatitis B knowledge and stigma on screening in Canadian Chinese population. Can J Gastroenterol 2012;26:597-602.

15. Uhanova J, Tate RB, Tataryn DJ, Minuk GY. A population-based study of the epidemiology of hepatitis C in a North American population. J Hepatol 2012;57:736-42.